SCHEMBL5319031

SCHEMBL5319031

COc1ccc(CN2CCN(CCO)CC2)c(OC)c1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.65
OPRK1 P41145 2/20 0.65
CYP1A2 P05177 1/20 0.65
SLC6A4 P31645 1/20 0.65
OPRD1 P41143 1/20 0.65
APOBEC3A P31941 1/20 0.63
CTDSP1 Q9GZU7 1/20 0.63
APOBEC3G Q9HC16 1/20 0.63
KDM4E B2RXH2 4/20 0.61
LMNA P02545 3/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
CYP2C19 P33261 1/20 0.60
HTT P42858 2/20 0.56
ADORA3 P0DMS8 1/20 0.56
CHRM1 P11229 1/20 0.56
DRD2 P14416 1/20 0.56
ADRA2B P18089 1/20 0.56
ADRA2C P18825 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28298203 0.89 CHRM2 (0.79) CHRM2OPRK1CYP1A2SLC6A4OPRD1
SCHEMBL10526447 0.88 SMN1; SMN2 (0.65) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Hydrochloric Acid SCHEMBL10960151 0.87 SMN1; SMN2 (0.64) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Hydrochloric Acid SCHEMBL10526466 0.87 SMN1; SMN2 (0.64) CHRM2OPRK1CYP1A2SLC6A4OPRD1
SCHEMBL30573473 0.86 CHRM2 (0.70) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Hydrochloric Acid SCHEMBL10526013 0.86 SMN1; SMN2 (0.62) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Hydrochloric Acid SCHEMBL10527455 0.86 SMN1; SMN2 (0.62) CHRM2OPRK1CYP1A2SLC6A4OPRD1
Hydrochloric Acid SCHEMBL10527215 0.86 SMN1; SMN2 (0.62) CHRM2OPRK1CYP1A2SLC6A4OPRD1
SCHEMBL5320057 0.85 CHRM2 (0.65) CHRM2OPRK1CYP1A2SLC6A4OPRD1
SCHEMBL11225310 0.84 CHRM2 (0.63) CHRM2OPRK1CYP1A2SLC6A4OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4100285-A VASODILATION NIPPON SHINYAKU CO., LTD. (JP) 1978-07-11 US claimed
US-12569480-B2 Methods of treating fibrosis using compounds that promote glucose oxidation IMBRIA PHARMACEUTICALS, INC. (US) 2026-03-10 US disclosed
US-20260060978-A1 METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE-BASED COMPOUNDS IMBRIA PHARMACEUTICALS INC (US) 2026-03-05 US disclosed
US-20250262310-A1 COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM IMBRIA PHARMACEUTICALS, INC. 2025-08-21 US disclosed
US-12318453-B2 Compositions and methods for increasing efficiency of cardiac metabolism IMBRIA PHARMACEUTICALS, INC. (US) 2025-06-03 US disclosed
US-12318382-B2 Methods of treating rheumatic diseases using trimetazidine-based compounds IMBRIA PHARMACEUTICALS, INC. (US) 2025-06-03 US disclosed
US-20240100173-A1 COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM IMBRIA PHARMACEUTICALS, INC. 2024-03-28 US disclosed
US-11844840-B2 Compositions and methods for increasing efficiency of cardiac metabolism IMBRIA PHARMACEUTICALS, INC. (US) 2023-12-19 US disclosed
US-20230399300-A1 METHODS OF SYNTHESIZING 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL] PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE IMBRIA PHARMACEUTICALS, INC. 2023-12-14 US disclosed
US-20230399300-A1 METHODS OF SYNTHESIZING 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL] PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE IMBRIA PHARMACEUTICALS, INC. 2023-12-14 US disclosed
US-20200138963-A1 COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM IMBRIA PHARMACEUTICALS, INC. 2020-05-07 US disclosed
CN-111093662-A Compositions and methods for improving cardiometabolic efficiency 安布里亚制药公司 2020-05-01 CN disclosed
WO-2020081361-A1 METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE-BASED COMPOUNDS IMBRIA PHARMACEUTICALS, INC. (US) 2020-04-23 WO disclosed
WO-2020081361-A1 METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE-BASED COMPOUNDS IMBRIA PHARMACEUTICALS, INC. (US) 2020-04-23 WO disclosed
US-10556013-B2 Compositions and methods for increasing efficiency of cardiac metabolism IMBRIA PHARMACEUTICALS, INC. (US) 2020-02-11 US disclosed
US-10556013-B2 Compositions and methods for increasing efficiency of cardiac metabolism IMBRIA PHARMACEUTICALS, INC. (US) 2020-02-11 US disclosed
US-20190216936-A1 COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM IMBRIA PHARMACEUTICALS, INC. 2019-07-18 US disclosed
US-20190216936-A1 COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM IMBRIA PHARMACEUTICALS, INC. 2019-07-18 US disclosed
US-20180360975-A1 COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM IMBRIA PHARMACEUTICALS, INC. 2018-12-20 US disclosed
WO-2007096251-A1 INHIBITORS OF CPT IN THE CENTRAL NERVOUS SYSTEM AS ANTIDIABETIC AND/OR ANTI-OBESITY DRUGS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12318382-B2 Methods of treating rheumatic diseases using trimetazidine-based compounds TRIM4, HMGCR, FAH CHRM2 1726/4885OPRK1 2681/4885CYP1A2 549/4885
US-20250262310-A1 COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM PC, PCK2, CPT1B CHRM2 2914/4885OPRK1 4692/4885CYP1A2 361/4885
US-10556013-B2 Compositions and methods for increasing efficiency of cardiac metabolism PC, PCK2, CPT1B CHRM2 2914/4885OPRK1 4692/4885CYP1A2 361/4885
US-20260060978-A1 METHODS OF TREATING RHEUMATIC DISEASES USING TRIMETAZIDINE-BASED COMPOUNDS TNNT2, TNNC1, CPT1B CHRM2 563/4885OPRK1 646/4885CYP1A2 1833/4885
US-20180360975-A1 COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM PC, PCK2, CPT1B CHRM2 2914/4885OPRK1 4692/4885CYP1A2 361/4885
US-20240100173-A1 COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM PC, PCK2, CPT1B CHRM2 2914/4885OPRK1 4692/4885CYP1A2 361/4885
US-12318453-B2 Compositions and methods for increasing efficiency of cardiac metabolism PC, PCK2, CPT1B CHRM2 2914/4885OPRK1 4692/4885CYP1A2 361/4885
US-20200138963-A1 COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM PC, PCK2, CPT1B CHRM2 2914/4885OPRK1 4692/4885CYP1A2 361/4885
US-12569480-B2 Methods of treating fibrosis using compounds that promote glucose oxidation CPT1B, PFKP, PTK2 CHRM2 336/4885OPRK1 2831/4885CYP1A2 1263/4885
US-11844840-B2 Compositions and methods for increasing efficiency of cardiac metabolism PC, PCK2, CPT1B CHRM2 2914/4885OPRK1 4692/4885CYP1A2 361/4885
US-20230399300-A1 METHODS OF SYNTHESIZING 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL] PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE TET3, TET2, TET1 CHRM2 3208/4885OPRK1 194/4885CYP1A2 139/4885
US-20190216936-A1 COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM PC, PCK2, CPT1B CHRM2 2914/4885OPRK1 4692/4885CYP1A2 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.